Generic vardenafil is the active-ingredient name used on FDA-approved prescription products for erectile dysfunction. The main U.S. product distinction is between conventional film-coated tablets and separate orally disintegrating presentations. Both involve vardenafil, but an identical milligram number does not make the two formulations interchangeable.
FDA approval is granted to defined drug applications with specified strengths, forms, labeling and manufacturers or applicants. A regulatory listing does not guarantee that a particular pharmacy can order the product today. The discontinued original U.S. Levitra and Staxyn brands also should not be confused with independently approved generic products.
This guide focuses on generic product identity and pharmacy verification, rather than telling patients which dose to take. For ingredient overview see vardenafil; for the former brand see Levitra; and for current purchasing steps see the U.S. pharmacy guide.
An approved generic is evaluated under the applicable abbreviated application system against a reference listed drug, including relevant quality and bioequivalence criteria. FDA’s Orange Book provides application and therapeutic-equivalence information, while the prescribing label identifies the exact dosage form and active ingredient.
The word generic does not mean every online product claiming vardenafil has passed FDA review. A foreign trade name, manufacturer advertisement or pharmacy search snippet cannot substitute for checking the actual U.S. approved application.
Conventional oral vardenafil tablets have been labeled in 2.5, 5, 10 and 20 mg strengths. Separate generic orally disintegrating vardenafil products have 10 mg labeling and administration rules derived from the historical Staxyn reference. The ODT formulation produces different systemic exposure from a 10 mg film-coated tablet.
This is clinically important: do not switch product forms or assume dose-for-dose equivalence. For complete context about the dissolving form, consult the vardenafil ODT page; for the four conventional strengths, see the strength directory.
FDA therapeutic-equivalence evaluations help a pharmacist identify products that may qualify for substitution under applicable law. The relevant comparison is product-specific, including form and strength, rather than a broad statement that every medicine bearing the vardenafil ingredient is equivalent.
Look up the exact approved application when necessary and ask the pharmacist which labeled product they intend to dispense. A product’s NDC helps identify a listed package, but an NDC by itself does not prove FDA approval, therapeutic equivalence or current availability.
Generic vardenafil can be identified through several independent fields. When information disagrees, request an explanation before taking the medicine.
The table separates approval and product identity from pharmacy stock. It is not a list of manufacturers claiming to have inventory.
| Record field | What it establishes | Important limit |
|---|---|---|
| Active ingredient | Vardenafil hydrochloride identity | Not enough to establish form equivalence |
| Application and approval | Specific U.S. regulatory authorization | Does not guarantee active retail supply |
| Dosage form | Film-coated tablet or ODT | A 10 mg form cannot automatically replace the other |
| Strength and imprint | Helps identify the dispensed tablet | May differ by generic labeler |
| NDC/package | Identifies a listed product package | Listing alone is not approval proof |
| Pharmacy label | Documents the actual fill | Check against the valid prescription |
Levitra was a branded film-coated vardenafil product, historically offered in multiple tablet strengths. Staxyn was a different 10 mg orally disintegrating brand. The original U.S. branded presentations were discontinued, but their reference labels can still inform searches and generic product evaluations.
An outdated price page, pharmacy database entry or package photo should not be interpreted as ongoing sales of either branded item. Check Staxyn’s brand history or Levitra’s history before treating a trade-name result as a current option.
A manufacturer’s drug label may enumerate 2.5, 5, 10 and 20 mg film-coated presentations; that is a product-label fact, not a live inventory feed. The 2.5 mg strength has particular legacy-brand and generic-listing history that warrants verifying the precise current application and dispensing source.
The 2.5 mg product page examines that distinction. Other strength pages explain product attributes individually without making clinical recommendations or assuming that all strengths are routinely stocked.
The active ingredient retains its contraindications with nitrates and riociguat. QT-prolongation precautions, relevant antiarrhythmics, alpha-blockers and other interacting medicines must be reviewed by the prescriber regardless of whether the medicine is labeled with a historic brand or a generic name.
An erection lasting more than four hours requires emergency evaluation; sudden vision or hearing changes require prompt medical attention. Read the interactions overview and the safety guide for those separate questions.
The pharmacy checks the valid prescription, permitted substitution rules and its actual inventory before dispensing. The patient should be able to ask which approved product, strength and form is being supplied and whether any change from the prescribed product has been reviewed.
If the intended generic is unavailable, the pharmacist may contact the prescriber about lawful alternatives; patients should not independently swap an ODT or tablet for a different strength or formulation. The local-pharmacy guide covers pickup details.
FDA approval does not determine one universal retail price or guarantee insurance coverage. Final cost depends on the exact product, pharmacy, quantity, benefits and other charges. A product’s approval status should be established before its cost is compared.
Use the evergreen cost guide for quote factors and the stock-verification guide for actual supply checks. Avoid unverified foreign products marketed as generic equivalents.
Read the pharmacy label and compare ingredient, form, strength, directions and quantity with the prescription. Ask about the tablet’s appearance or imprint if the product differs from a previous fill; changes may be legitimate but still deserve identification.
Finally, ensure the pharmacist has reviewed contraindications and interactions. Regulatory equivalence is a precise technical concept—not a guarantee of personal treatment success or permission to alter a clinician’s instructions.
FDA has approved specific generic vardenafil applications. Approval must be checked for the exact formulation, strength and product, not inferred from an advertisement.
Conventional generic vardenafil products share the active ingredient, while approval and permitted substitution must be confirmed for the specific dosage form and strength.
No. Their prescribing information identifies formulation-related exposure differences, so milligram-for-milligram substitution should not be assumed.
The original U.S. branded presentations were discontinued. Generic products must be assessed independently.
No. A product listing or NDC is not by itself proof of FDA approval or therapeutic equivalence.
Substitution depends on the exact approved product, applicable therapeutic-equivalence information, state law and the prescriber’s directions.
No. Approved status, labeling and real-time pharmacy inventory are different facts.
No. Vardenafil for ED is prescription-only in the United States.